Oppenheimer Asset Management Inc. Buys 604 Shares of Insulet Co. (NASDAQ:PODD)

Oppenheimer Asset Management Inc. grew its stake in shares of Insulet Co. (NASDAQ:PODD) by 2.9% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 21,226 shares of the medical instruments supplier’s stock after acquiring an additional 604 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Insulet were worth $4,940,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of PODD. Blue Trust Inc. grew its position in shares of Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 58 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in Insulet in the second quarter worth about $32,000. Venturi Wealth Management LLC lifted its stake in Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 133 shares during the period. UMB Bank n.a. grew its holdings in Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after acquiring an additional 81 shares in the last quarter. Finally, CVA Family Office LLC increased its position in Insulet by 138.1% during the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after purchasing an additional 145 shares during the period.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PODD. Piper Sandler upped their price target on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Morgan Stanley increased their target price on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday. Sanford C. Bernstein initiated coverage on Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target for the company. Raymond James upped their price objective on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research note on Monday, October 14th. Finally, Barclays lifted their target price on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $253.27.

Insulet Price Performance

Shares of NASDAQ PODD opened at $261.16 on Friday. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $279.40. The business’s 50 day moving average price is $236.86 and its 200 day moving average price is $206.85. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The firm has a market cap of $18.32 billion, a P/E ratio of 44.72, a P/E/G ratio of 4.11 and a beta of 1.22.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.